ION582
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Angelman Syndrome
Conditions
Angelman Syndrome
Trial Timeline
Dec 22, 2021 → Mar 1, 2029
NCT ID
NCT05127226About ION582
ION582 is a phase 1/2 stage product being developed by Ionis Pharmaceuticals for Angelman Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05127226. Target conditions include Angelman Syndrome.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05127226 | Phase 1/2 | Recruiting |
Competing Products
9 competing products in Angelman Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| RO7248824 | Roche | Phase 1 | 33 |
| RO7248824 | Roche | Phase 1 | 33 |
| Alogabat | Roche | Phase 2 | 52 |
| ION582 + Placebo | Ionis Pharmaceuticals | Phase 3 | 74 |
| GTX-102 | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| GTX-102 | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| GTX-102 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| GTX-102 | Ultragenyx Pharmaceutical | Phase 1/2 | 36 |
| NNZ-2591 | Neuren Pharmaceuticals | Phase 2 | 47 |